Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study

• Published in: Seminars in arthritis and rheumatism Vol. 69; p. 152560
• Main Authors: Conticini, Edoardo, Cameli, Paolo, Grazzini, Silvia, d'Alessandro, Miriana, Bergantini, Laura, Porcelli, Brunetta, Mazzei, Maria Antonietta, Cantarini, Luca, Bargagli, Elena, Frediani, Bruno
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2024
• Subjects: Adult; Aged; Anti-synthethase syndrome; Arthritis; Drug Tapering; Drug Therapy, Combination; Female; Glucocorticoids; Glucocorticoids - administration & dosage; Glucocorticoids - therapeutic use; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - therapeutic use; Interstitial lung disease; Male; Methotrexate - administration & dosage; Methotrexate - therapeutic use; Middle Aged; Myositis; Myositis - drug therapy; Pilot Projects; Prednisone - administration & dosage; Prednisone - therapeutic use; Prospective Studies; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Rituximab - therapeutic use; Treatment Outcome; Rituximab; Myositis; Arthritis; Anti-synthethase syndrome; Glucocorticoids; Interstitial lung disease

Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints, and lungs. Despite increasing interest and evidence, optimal clinical management remains unclear due to a...